Celltrion Healthcare Co., Ltd.
091990
Classifica tra le azioni
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Prezzo delle azioni
$57.75
Ultima sincronizzazione: 2024-01-11
Capitalizzazione di mercato
$9.42B
Variazione (1 giorno)
-0.25%
Variazione (1 anno)
0.00%
Paese
KR
Scambia Celltrion Healthcare Co., Ltd. (091990)
Categoria
Healthcare
Rapporto P/B per Celltrion Healthcare Co., Ltd. (091990)
Rapporto P/B al October 2026 TTM: 5.94
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Celltrion Healthcare Co., Ltd., il rapporto P/B attuale (TTM) è 5.94. Alla fine del 2021, era pari a 6.21.
Storico del rapporto P/B per Celltrion Healthcare Co., Ltd. da 2014 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 5.94 | 32.24% |
| 2022 | 4.49 | -27.70% |
| 2021 | 6.21 | -15.82% |
| 2020 | 7.38 | -12.83% |
| 2019 | 8.46 | -1.92% |
| 2018 | 8.63 | 5.42% |
| 2017 | 8.19 | -50.80% |
| 2016 | 16.64 | 27.60% |
| 2015 | 13.04 | 10,587.95% |
| 2014 | 0.12 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | 5.28% |
US
|
|
| 13.2547 | 123.23% |
US
|
|
| 4.4521 | -25.02% |
AU
|
|
| 6.3632 | 7.17% |
NL
|
|
| - | - |
CH
|
